导师信息 当前所在位置: 首页 >> 师资与博后 >> 研究生导师 >> 导师信息
田赟 副主任医师,讲师

硕士招生类型:学术型;专业型

硕士招生专业:肿瘤学

博士招生类型:

博士招生专业:

所在院系:附属上海市皮肤病医院
联系方式:1801231@tongji.edu.cn ; 976538415@qq.com
课题组链接:
研究方向
主要任职
科研业绩

基础研究:肠道微生态影响PD-1单抗在包括恶性黑色素瘤在内的实体瘤的免疫治疗。我们的研究团队聚焦炎性肠病和结直肠癌粘膜免疫紊乱的研究。我们团队早先的研究发现阿司匹林通过干预IL-6/STAT3/SOCS3信号通路在肠炎相关肠癌中发挥作用。近年来团队聚焦炎症和癌症的关系研究,尤其慢性肠炎相关肠癌的研究。评估谷氨酰胺、膳食纤维和改善肠道菌群在肠炎相关肠癌中的作用,并通过抗炎作用最终达到延缓和治疗炎性癌变。

临床研究:为实体瘤患者提供最好的治疗策略,并根据AJCC分期和NCCN指南筛选病人,为病情需要的患者提供适合的临床试验。

Basic research: Gut microbiome influences efficacy of PD-1-based immunotherapy against solid tumors including melanoma. Mainly focusing on the mucosal immune disorders in the pathogenesis of inflammatory bowel disease and the carcinogenesis of colorectal cancer. The effects of aspirin on aberrant IL-6/STAT3/SOCS3 signaling pathway in colitis-associated colorectal cancer (CAC) have been explored in our work in recent years. Focusing on the aberrant signaling pathway existed in both inflammatory bowel disease and inflammation-related gastrointestinal cancers, especially CAC. Evaluating the possibility of oral glutamine, SCFAS, and intestinal bacteria on the development of CAC, and explore the chemoprevention mechanisms of anti-inflammation agents on the tumorigenesis.

Clinical research: Provide the optimal treatment strategy for patients with solid tumors. According the 7th edition of the AJCC staging system and the clinical presentation of the patient, we evaluated the clinical staging, and provide the optimal adjuvant treatment. When appropriate, patients should preferentially be included in a clinical trial over standard or accepted therapy.


Copyright  2017 同济大学医学院 版权所有 同济大学医学院主办  All Rights Reserved